Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Phase 2 trial evaluates entospletinib in DLBCL

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Key clinical point: Entospletinib has limited activity against relapsed/refractory diffuse large B-cell lymphoma and a high rate of adverse events.

Major finding: The rate of progression-free survival at 16 weeks was 3.6% with a median PFS of 1.5 months.

Study details: An analysis of 43 relapsed/refractory DLBCL patients who received single-agent entospletinib.

Disclosures: The study was supported by Gilead Sciences. Dr. Burke reported relationships with Gilead and other companies.

Read the article here.

Citation:

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331.